New Guidance on Investigational Medicinal Products (IMPs) and Non Investigational Medicinal products (NIMPs)
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The EU Commission has published a revision of the Guidance on Investigational Medicinal Products (IMPs) and Non investigational Medicinal Products (NIMPs), which had been published in 2007, completing the detailed guidance CT-1. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NIMPs in the application dossier.
In 3.3., it is pointed out that documentation requirements in the application dossier for IMPs also apply to NIMPs. However, depending on the knowledge of the NIMP, documentation can be reduced to a so called 'simplified dossier' described in detail in Annex 2 of the document. To determine the required data, a risk-based approach needs to be applied.
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development